Cyclacel Pharma (CYCC) Reports Q3 Loss of $0.11/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Cyclacel Pharma (CYCC) Reports Q3 Loss of $0.11/Share

Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results

November 13, 2019 4:05 PM EST

Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent

Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET

BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported financial results and business highlights for the third quarter 2019.  The Company's net loss applicable to common shareholders for the three months ended September 30, 2019 was $2.0 million. As of September 30, 2019 cash and cash equivalents totaled $13.0 million.

The investigators evaluating CYC065, our... More